The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Current Pollinosis Treatments Least Effective at Relieving Nasal Congestion: MSD
January 12, 2012
- Kyowa Kirin President Matsuda Aims for Global Presence in Biosimilar Business
January 11, 2012
- DSP to Change Brand Name of Almarl to Avoid Confusion
January 11, 2012
- Kyowa Hakko Kirin to Develop Expert MRs to Boost Cancer Field
January 11, 2012
- Nipro to Set Up Pharmaceutical Plant in Vietnam for Contract Manufacturing of Generics
January 11, 2012
- Interprotein, Takeda to Collaborate on Molecular Designing of PPI Modulators
January 11, 2012
- Observation Period Ended in PII/III Trial of Elpamotide: OncoTherapy
January 11, 2012
- DWTI’s Antiplatelet Agent Enters Late PII Stage
January 11, 2012
- Bayer Submits Rivaroxaban in EU, US for Add’l Indication
January 11, 2012
- Top Managements of Pharmaceutical Companies Express Complaints for Additional Price Cut for Long-Listed Drugs
January 10, 2012
- Bayer Yakuhin to Promote Long-Listed Products Without Mediation by MRs
January 10, 2012
- Bayer Yakuhin President Guth Says Marketing Success of 2 Strategic Products Key Focus
January 10, 2012
- Toho HD Chairman Matsutani Showed Enthusiasm for 3rd Round of Distribution Improvement Talks
January 10, 2012
- Takeda and Osaka Univ. Establish Joint Research Chair for Nano-particle Vaccines
January 10, 2012
- Astellas Terminates License Agreement for VIBATIV Injection
January 10, 2012
- Asahi Kasei Pharma Launches Flivas in South Korea through Dong-A
January 10, 2012
- Pharmacist Survey Shows Meiji Seika Pharma Rise to 3rd Rank for “Memorable” MRs
January 6, 2012
- Deutsche Securities Report Says Patent Cliff Concerns Scarce for MTPC
January 6, 2012
- AZ President Hudson Says Development of Japanese Leaders One of Key Company Issues
January 6, 2012
- AZ to Utilize E-detailing, Optimize According to Product
January 6, 2012
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…